Multiple Myeloma


Sterotherapeutics’ ST004 is a highly selective novel matrix metallaoproteinase-13 (MMP-13) inhibitor licensed from the Moffitt Cancer Center/ FAU with no apparent off-target MMP inhibition thereby solving the foremost problem with the class of drugs. It is also noteworthy that ST004 exhibits no collagenolysis and no MSS.

Matrix Metallaoproteinase-13 overexpression has been strongly correlated to multiple myeloma through the promotion of osteoclastogenesis. Due to MMP-13 over activity in the number of osteoclasts (bone destruction) increases whilst the number of osteoblasts (bone formation) decreases. In addition to the Increase in the number of osteoclasts the destructive activity is enhanced due to a increase in osteoclast polynucelation. It is also noteworthy that the number of abnormal (malignant) plasma cells is reduced. This has made MMP-13 inhibition a prime target for the treatment of multiple myeloma.


Efforts to develop MMP-13 inhibitor have met with failure due primarily to off-target adverse events (AE) due to the lack of selectivity for other MMPs. Muscle skeletal syndrome (MSS) has been the most frequently reported AE due in part to a breakdown of collagen. Other issues have plagued MMP-13 inhibitors such a stability, bioavailability, and cell permeability.